Enzon Pharmaceuticals (ENZN) 10-Q 5 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Oct. 29, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Enzon Pharmaceuticals, Inc.
Entity Central Index Key	0000727510
Current Fiscal Year End Date	--12-31
Entity File Number	001-36435
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-2372868
Entity Address, Address Line One	20 Commerce Drive (Suite 135)
Entity Address, City or Town	Cranford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07016
City Area Code	732
Local Phone Number	980-4500
Title of 12(b) Security	None
No Trading Symbol Flag	true
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,214,603

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 47,891	$ 48,142
Royalty and milestone receivable		31
Other current assets	72	59
Total assets (all current)	47,963	48,232
Current liabilities:
Accounts payable	331	302
Accrued expenses and other current liabilities	46	110
Total current liabilities	377	412
Commitments and contingencies
Stockholders' equity:
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at September 30, 2021 and December 31, 2020	0	0
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at September 30, 2021 and December 31, 2020	742	742
Additional paid-in capital	76,488	78,006
Accumulated deficit	(71,622)	(71,388)
Total stockholders' equity	5,608	7,360
Total liabilities, mezzanine equity and stockholders' equity	47,963	48,232
Series C Preferred Stock
Mezzanine equity:
Series C preferred stock - $0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value $1,050 and $1,012 per share) at September 30, 2021 and December 31, 2020	$ 41,978	$ 40,460

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
MEZZANINE EQUITY
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,960,000	2,960,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	74,214,603	74,214,603
Common stock, shares outstanding	74,214,603	74,214,603
Series C Preferred Stock
MEZZANINE EQUITY
Preferred Shares, par value	$ 0.01	$ 0.01
Preferred Shares, shares authorized	40,000	40,000
Preferred Shares, shares issued	40,000	40,000
Preferred Shares, shares outstanding	40,000	40,000
Preferred Shares, liquidation value	$ 1,050	$ 1,012

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Royalties and milestones, net	$ 0	$ 8	$ 672	$ 18
Total revenues	0	8	672	18
Operating expenses:
General and administrative	228	415	910	901
Total operating expenses	228	415	910	901
Operating loss	(228)	(407)	(238)	(883)
Other income	2	0	6	0
Loss before income tax expense	(226)	(407)	(232)	(883)
Income tax expense	0	0	2	2
Net loss	(226)	(407)	(234)	(885)
Dividends on Series C preferred stock	(506)	0	(1,518)	0
Net loss available to common shareholders	$ (732)	$ (407)	$ (1,752)	$ (885)
Loss per common share
Basic loss per share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Diluted loss per share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted-average number of shares - basic	74,215	44,215	74,215	44,215
Weighted-average number of shares - diluted	74,215	44,215	74,215	44,215

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY - USD ($)	Series C Preferred StockPreferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019		$ 442,000	$ 75,690,000	$ (70,077,000)	$ 6,055,000
Balance (in shares) at Dec. 31, 2019		44,215
Net loss	$ 0	$ 0	0	(242,000)	(242,000)
Balance at Mar. 31, 2020		$ 442,000	75,690,000	(70,319,000)	5,813,000
Balance (in shares) at Mar. 31, 2020		44,215
Balance at Dec. 31, 2019		$ 442,000	75,690,000	(70,077,000)	6,055,000
Balance (in shares) at Dec. 31, 2019		44,215
Net loss					(885,000)
Balance at Sep. 30, 2020		$ 442,000	75,690,000	(70,962,000)	5,170,000
Balance (in shares) at Sep. 30, 2020		44,215
Balance at Mar. 31, 2020		$ 442,000	75,690,000	(70,319,000)	5,813,000
Balance (in shares) at Mar. 31, 2020		44,215
Net loss	0	$ 0	0	(236,000)	(236,000)
Balance at Jun. 30, 2020		$ 442,000	75,690,000	(70,555,000)	5,577,000
Balance (in shares) at Jun. 30, 2020		44,215
Net loss	0	$ 0	0	(407,000)	(407,000)
Balance at Sep. 30, 2020		$ 442,000	75,690,000	(70,962,000)	5,170,000
Balance (in shares) at Sep. 30, 2020		44,215
Balance at Dec. 31, 2020	$ 40,460,000	$ 742,000	78,006,000	(71,388,000)	7,360,000
Balance (in shares) at Dec. 31, 2020	40	74,215
Net loss	$ 0	$ 0	0	11,000	11,000
Preferred stock dividend accumulation	(506,000)		(506,000)		(506,000)
Balance at Mar. 31, 2021	$ 40,966,000	$ 742,000	77,500,000	(71,377,000)	6,865,000
Balance (in shares) at Mar. 31, 2021	40	74,215
Balance at Dec. 31, 2020	$ 40,460,000	$ 742,000	78,006,000	(71,388,000)	7,360,000
Balance (in shares) at Dec. 31, 2020	40	74,215
Net loss					(234,000)
Balance at Sep. 30, 2021	$ 41,978,000	$ 742,000	76,488,000	(71,622,000)	5,608,000
Balance (in shares) at Sep. 30, 2021	40	74,215
Balance at Mar. 31, 2021	$ 40,966,000	$ 742,000	77,500,000	(71,377,000)	6,865,000
Balance (in shares) at Mar. 31, 2021	40	74,215
Net loss	$ 0	$ 0	0	(19,000)	(19,000)
Preferred stock dividend accumulation	(506,000)		(506,000)		(506,000)
Balance at Jun. 30, 2021	$ 41,472,000	$ 742,000	76,994,000	(71,396,000)	6,340,000
Balance (in shares) at Jun. 30, 2021	40	74,215
Net loss	$ 0	$ 0	0	(226,000)	(226,000)
Preferred stock dividend accumulation	(506,000)		(506,000)		(506,000)
Balance at Sep. 30, 2021	$ 41,978,000	$ 742,000	$ 76,488,000	$ (71,622,000)	$ 5,608,000
Balance (in shares) at Sep. 30, 2021	40	74,215

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (234)	$ (885)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities	(17)	1,050
Net cash (used in) provided by operating activities	(251)	165
Cash flows from financing activities:
Payment of deferred stock offering expenses	0	(300)
Net cash used in financing activities	0	(300)
Net decrease in cash	(251)	(135)
Cash beginning of period	48,142	5,446
Cash end of period	47,891	5,311
Supplemental non-cash financing disclosure:
Deferred stock offering expenses	$ 0	$ 157

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2021
Description of Business
Description of Business	(1) Description of Business Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the “Company,” “Enzon,” “we” or “us”) is positioned as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss carryforwards (“NOLs”) and enhance stockholder value. In September 2020, the Company initiated a rights offering for its common and preferred stock (see below and Note 12 to its Condensed Consolidated Financial Statements), which closed in October 2020, and it realized $43.6 million in gross proceeds. This has enabled the Company to embark on its plan to realize the value of its approximately $103.5 million net operating loss carryforwards (“NOLs”) by acquiring potentially profitable businesses or assets. To protect the NOLs, in August 2020, the Company’s Board of Directors adopted a Section 382 rights plan (see Note 11 to our Condensed Consolidated Financial Statements). Historically, the Company had received royalty revenues from licensing arrangements with other companies primarily related to sales of certain drug products that utilized Enzon’s proprietary technology. In recent years, the Company has had no clinical operations and limited corporate operations. The Company has a marketing agreement with Micromet AG, now part of Amgen, Inc. (the “Micromet Agreement”), pursuant to which the Company may be entitled to a share of certain milestone and royalty payments if Vicineum, a drug being developed by Sesen Bio, Inc. (“Sesen”), is approved for the treatment of non-muscle invasive bladder cancer. In a press release dated February 16, 2021, Sesen announced that the U.S. Food and Drug Administration (the “FDA”) has accepted for filing Sesen’s Biologic License Application (“BLA”) for Vicineum. The FDA further granted Priority Review, with a target Prescription Drug User Fee Act (“PDUFA”) date for a decision on the BLA of August 18, 2021. Accordingly, the Company earned a milestone of $409,430 in the first quarter of 2021, which was fully paid by June 30, 2021. On August 13, 2021, Sesen announced that it had received a Complete Response Letter (“CRL”) from the FDA and that the FDA had determined that it cannot approve the BLA for Vicineum in its present form and had provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (“CMA”) issues pertaining to a recent preapproval inspection and product quality. In a press release that Sesen issued on November 1, 2021, it noted that on October 29, 2021 it had a CMA Type A meeting with the FDA and reviewed issues related to CMC that will be further discussed during the review of the BLA for Vicineum upon potential resubmission. Sesen, also noted that it is preparing for the clinical Type A meeting to discuss the recommendations specific to additional clinical/statistical data and analyses that the FDA raised in the CRL. It expects that meeting to take place later in 2021. In a filing with the U. S. Securities and Exchange Commission (“SEC”) in March 2021, Sesen noted that it had received notice from the European Medicines Agency (“EMA”) that its Marketing Authorization Application (“MMA”) for Vicineum was found to be valid and the review procedure has officially started. Accordingly, the Company received an additional milestone payment of $292,284 during the quarter ended June 30, 2021. Subsequently, on August 25, 2021, Sesen announced that it had withdrawn its application to market Vicineum in Europe. Due to the challenges associated with developing and obtaining approval for drug products, and the lack of involvement by the Company in the development and approval process, there is substantial uncertainty as to whether the Company will receive additional milestone or any royalty payments under the Micromet Agreement or any other agreements. The Company will not recognize revenue until all revenue recognition requirements are met. The Company maintains its principal executive offices at 20 Commerce Drive, Suite 135, Cranford, New Jersey 07016 through a service agreement with Regus Management Group, LLC.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Basis of Presentation
Basis of Presentation	(2) Basis of Presentation Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (SEC). Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. Revenue Recognition Royalty revenues from the Company’s agreements with third parties are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues. Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as revenue when the milestone has been achieved and collection is assured, such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Recent Accounting Pronouncements
Recent Accounting Pronouncements	(3) Recent Accounting Pronouncements Recent Accounting Standards Updates issued by the Financial Accounting Standards Board and guidance issued by the Securities and Exchange Commission did not, or are not believed by management to, have a material effect on the Company’s present or future Condensed Consolidated Financial Statements.

Financial Instruments and Fair

Financial Instruments and Fair Value	9 Months Ended
	Sep. 30, 2021
Financial Instruments and Fair Value
Financial Instruments and Fair Value	(4) Financial Instruments and Fair Value The carrying values of cash and cash equivalents, royalty and milestone receivable, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s consolidated balance sheets approximated their fair values at September 30, 2021 and December 31, 2020 due to their short-term nature. As of both September 30, 2021 and December 31, 2020, the Company held cash equivalents (generally, funds that invest more than 99.5 percent of their assets in U.S. Treasury bills, notes and other obligations issued or guaranteed as to principal and interest by the U. S. government) aggregating approximately $43.6 million.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Information
Supplemental Cash Flow Information	(5) Supplemental Cash Flow Information The Company made no income tax payments during the three and nine-month periods ended September 30, 2021 and 2020. There were no interest payments made during the three and nine-month periods ended September 30, 2021.

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Loss Per Common Share
Loss Per Common Share	(6) Loss Per Common Share Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during the period. Restricted stock awards and restricted stock units (collectively, nonvested shares) are not considered to be outstanding shares until the service or performance vesting period has been completed. The diluted earnings per share calculation would normally involve adjusting both the denominator and numerator as described here if the effect is dilutive. For purposes of calculating diluted earnings per common share, the denominator normally includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Because a loss was incurred in each of the three and nine-month periods ended September 30, 2021 and 2020, common stock equivalents would be anti-dilutive and, accordingly, were excluded from the calculation of diluted loss per share in each of the periods. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan. During each of the three and nine-month periods ended September 30, 2021 and 2020, there were no common stock equivalents. Loss per common share information is as follows (in thousands, except per share amounts) for the three months and nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Nine months ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Loss Per Common Share – Basic and Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (226) ​ $ (407) ​ $ (234) ​ $ (885) Dividends on Series C preferred stock ​ ​ (506) ​ ​ — ​ ​ (1,518) ​ ​ — Net loss available to common shareholders ​ $ (732) ​ $ (407) ​ $ (1,752) ​ $ (885) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average number of common shares outstanding ​ 74,215 ​ 44,215 ​ ​ 74,215 ​ 44,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted loss per share ​ $ (0.01) ​ $ (0.01) ​ $ (0.02) ​ $ (0.02) ​ For the nine-month periods ended September 30, 2021 and 2020 and the three-month periods ended September 30, 2021 and 2020, there were 25,000 and 41,787 potentially dilutive securities outstanding that have been excluded from the calculation of dilutive weighted average shares outstanding, as they would be anti-dilutive.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2021
Stock Based Compensation
Stock Based Compensation	(7) Stock-Based Compensation Stock Options and Restricted Stock Units (RSUs or Nonvested Shares) During the nine months ended September 30, 2021, no options were granted, and the Company incurred no stock-based compensation expense. No RSUs were outstanding as of September 30, 2021. There were no options granted during the nine months ended September 30, 2020 and no nonvested shares granted or outstanding Activity related to stock options and nonvested shares during the nine months ended September 30, 2021 and related balances outstanding as of that date are reflected below (in thousands): ​ ​ ​ ​ ​ ​ Stock Options Outstanding at January 1, 2021 25,000 Granted — Exercised and vested — Expired and forfeited — Outstanding at September 30, 2021 25,000 ​ ​ ​ Options vested at September 30, 2021 25,000 ​ ​ ​ Options exercisable at September 30, 2021 25,000 ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Taxes
Income Taxes	(8) Income Taxes During each of the three and nine-month periods ended September 30, 2021, the Company recorded approximately $0 and $2,000 of income tax expense for New Jersey state income tax. During the three and nine-month periods ended September 30, 2020, the Company recorded approximately $0 and $2,000, respectively, of income tax expense for New Jersey state income tax. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For the period ended December 31, 2020, the Company believed that it was more likely than not that future taxable income would not exist to utilize some or all of its deferred tax assets. However, although there can be no certainty of such, if the Company’s acquisition strategy is successful and future taxable income is projected, among other things, the valuation allowance will be reevaluated. Accordingly, the Company recorded a valuation allowance in the amount of its total deferred tax assets for the period ended December 31, 2020. In 2021, the Company projects a taxable loss before utilization of NOLs. Due to the valuation allowance placed on its deferred tax assets, the deferred tax expense resulting from the usage and/or expiration of deferred tax assets was offset by a corresponding deferred tax benefit from a reduction in valuation allowance, and the Company recorded no deferred tax expense as of September 30, 2021. The Company intends to acquire profitable businesses, entities or revenue streams that will generate sufficient income so that it can utilize its approximately $103.5 million NOLs. To date, no actionable acquisition candidates have been identified and, while the Company expects that, ultimately, it will be successful in realizing the value of its NOLs, the Company cannot provide assurance that it will be able to do so. Management of the Company will continue to assess the need for this valuation allowance and will make adjustments when or if appropriate. At September 30, 2021, the Company had federal NOLs of approximately $103.5 million, of which approximately $100.6 million will expire in the years 2025 through 2036, and New Jersey state NOLs of approximately $25.8 million that expire in the years 2031 through 2041. Under the Tax Cuts and Jobs Act, net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income. The Coronavirus Aid, Relief and Economic Security Act, which was signed into law on March 27, 2020, suspended the 80% limitation for taxable years 2018 through 2020 and provided for a five-year carryback period for net operating losses for those years. Net operating losses generated in 2017 and earlier continue to be carried forward for 20 years and have no 80% limitation on utilization.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2021
Commitments and Contingent Liabilities
Commitments and Contingent Liabilities	(9) Commitments and Contingent Liabilities In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was reported in Wuhan, China. On March 11, 2020, the World Health Organization characterized the global spread of COVID-19 as a pandemic. In an effort to slow the spread of the virus, the United States and many other countries around the world imposed restrictions on non-essential work activities, travel and mass gatherings. Although these restrictions have been eased in some areas, it is not known whether these lockdowns and other restrictions will be reintroduced, especially in light of the uncertainty regarding cases in the United States, including the impact of the Delta variant, when they will end or the ultimate impact these unprecedented actions will have on the Company’s financial condition and prospects. At the present time, the Company’s business activities have been largely unaffected by COVID-19 restrictions as the Company’s workforce is comprised solely of independent contractors who are able to perform their duties remotely. However, these restrictions may impact the third parties who are responsible for obtaining final approval of and manufacturing product candidates for which the Company shares the right to receive licensing fees, milestone payments and royalty revenues. If those third parties are required to curtail their business activities for a significant time, or if global supply chain disruptions impact their ability to procure needed resources, raw materials or components, the Company’s right to receive licensing fees, milestone payments or royalties could be materially and adversely affected. Additionally, the development timeline for product candidates being developed by third parties that are pending FDA or other regulatory approval could be delayed if the agency is required to shift resources to the review and approval of candidates for treatment of COVID-19. In addition, the effects of the COVID-19 pandemic, including the current global challenges, may negatively impact the Company’s search for a business acquisition or investment, as well as negatively impacting the business and/or results of operations of any target business which the Company acquires or in which it invests. The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

Accounts Payable

Accounts Payable	9 Months Ended
	Sep. 30, 2021
Accounts Payable
Accounts Payable	(10) Accounts Payable Due to returns, rebates and other adjustments, at various times, Merck has notified the Company of its expected repayment of previously paid royalties. As of December 31, 2020, according to Merck, the Company had a net liability to Merck (net of a 25% royalty interest that the Company had previously sold) aggregating approximately $302,000. This was based on Merck’s assertions regarding the net result of overpayments, rebates and returns related to prior periods sales of PegIntron. Merck expected to be repaid for such overpayments through reductions of future royalties earned by the Company. During the three months ended March 31, 2021, Merck notified the Company of an additional amount they believe is owed to them approximating $27,000. During the three months ended June 30, 2021, Merck notified the Company of an additional amount they believe is owed to them approximating $2,000. During the three months ended September 30, 2021, Merck reported minimal royalties earned by the Company. Accordingly, at September 30, 2021, the Company recorded a net payable to Merck of approximately $331,000 due to such royalty overpayment claims by Merck. The Company believes that it will receive no material additional royalties from Merck.

Section 382 Rights Plan

Section 382 Rights Plan	9 Months Ended
	Sep. 30, 2021
Section 382 Rights Plan.
Section 382 Rights Plan	(11) Section 382 Rights Plan On August 14, 2020, in an effort to protect stockholder value by attempting to protect against a possible limitation on the Company’s ability to use its NOLs, the Company’s Board of Directors adopted a Section 382 rights plan and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on August 24, 2020. Accordingly, holders of the Company’s common stock own one preferred stock purchase right for each share of common stock owned by such holder. The rights are not immediately exercisable and will become exercisable only upon the occurrence of certain events as set forth in the Section 382 rights plan. If the rights become exercisable, each right would initially represent the right to purchase from the Company one one-thousandth of a share of the Company’s Series A-1 Junior Participating Preferred Stock, par value $0.01 per share, for a purchase price of $1.20 per right. If issued, each fractional share of Series A-1 Junior Participating Preferred Stock would give the stockholder approximately the same dividend, voting and liquidation rights as does one share of the Company’s common stock. However, prior to exercise, a right does not give its holder any rights as a stockholder of the Company, including any dividend, voting or liquidation rights. The rights will expire on the earliest of (i) the close of business on June 2, 2024 (unless that date is advanced or extended by the Board), (ii) the time at which the rights are redeemed or exchanged under the Section 382 rights plan, (iii) the close of business on the day of repeal of Section 382 of the Internal Revenue Code or any successor statute or (iv) the close of business on the first day of a taxable year of the Company to which the Company’s Board of Directors determines that no NOLs may be carried forward. The Company received stockholder ratification of the Section 382 rights plan at the Company’s 2021 annual meeting held June 2, 2021. In connection with the stockholder ratification, on June 4, 2021, effective as of June 2, 2021, the Company amended the Section 382 rights plan to extend the original expiration date from the close of business on August 13, 2021 to the close of business on June 2, 2024.

Rights Offering

Rights Offering	9 Months Ended
	Sep. 30, 2021
Rights Offering.
Rights Offering	(12) Rights Offering In September 2020, the Company’s Board of Directors approved a Rights Offering (the “Rights Offering”), by which the Company distributed, at no charge to all holders of its common stock on September 23, 2020 (the “Record Date”), transferable subscription rights to purchase units (“Units”) at a subscription price per Unit of $1,090. In the Rights Offering, each stockholder on the Record Date received one subscription right for every share of common stock owned on the Record Date. For every 1,105 subscription rights held, a stockholder was entitled to purchase one Unit at the subscription price. Each Unit consisted of one share of newly designated Series C Preferred Stock, par value $0.01 per share, and 750 shares of the Company’s common stock. The subscription period for the Rights Offering ended on October 9, 2020. As a result of the sale of all 40,000 Units available for purchase in the Rights Offering, the Company received approximately $43.6 million of gross proceeds and had 40,000 shares of Series C Preferred Stock outstanding and an aggregate of 74,214,603 shares of common stock outstanding following the Rights Offering. Pursuant to the Rights Offering, Icahn Capital LP, together with its affiliates, subscribed for 5,971 Units (its pro-rata share of the Rights Offering) representing the purchase of 4,478,250 shares of the Company’s common stock and 5,971 shares of Series C Preferred Stock. Icahn Capital LP also purchased all Units that remained unsubscribed for at the expiration of the Rights Offering to the extent that other holders elected not to exercise all of their respective subscription rights, which totaled 33,306 Units representing the purchase of 24,979,500 shares of common stock and 33,306 shares of Series C Preferred Stock. Following the completion of the Rights Offering, Icahn Capital LP, together with its affiliates, owned approximately 48% of the Company’s outstanding common stock and approximately 98% of the Company’s outstanding Series C Preferred Stock.

Series C Preferred Stock

Series C Preferred Stock	9 Months Ended
	Sep. 30, 2021
Series C Preferred Stock.
Series C Preferred Stock	(13) Series C Preferred Stock In October 2020, the Company issued 40,000 shares of Series C Preferred Stock for an aggregate purchase price of $40.0 million. On December 31 st As of September 30, 2021, June 30, 2021 and March 31, 2021, pursuant to the terms of the Series C Preferred Stock, the Company’s Board of Directors had not declared a cash dividend on the Series C Preferred Stock as dividends on such stock are only declared and paid once a year on or about December 31 st The Company may not repurchase or redeem the Series C Preferred Stock prior to November 1, 2022. Since the redemption of the Series C Preferred Stock is contingently or optionally redeemable, the Series C Preferred Stock has been classified in mezzanine equity on the Consolidated Balance Sheets.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events
Subsequent Events	(14) Subsequent Event On November 1, 2021, Jennifer McNealey tendered her resignation as a director from the Board of Directors of the Company, effective November 8, 2021. The decision by Ms. McNealey to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Basis of Presentation
Interim Financial Statements	Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (SEC). Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition	Revenue Recognition Royalty revenues from the Company’s agreements with third parties are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues. Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as revenue when the milestone has been achieved and collection is assured, such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Loss Per Common Share
Schedule of loss per common share information, basic and diluted	Loss per common share information is as follows (in thousands, except per share amounts) for the three months and nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Nine months ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Loss Per Common Share – Basic and Diluted: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (226) ​ $ (407) ​ $ (234) ​ $ (885) Dividends on Series C preferred stock ​ ​ (506) ​ ​ — ​ ​ (1,518) ​ ​ — Net loss available to common shareholders ​ $ (732) ​ $ (407) ​ $ (1,752) ​ $ (885) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average number of common shares outstanding ​ 74,215 ​ 44,215 ​ ​ 74,215 ​ 44,215 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted loss per share ​ $ (0.01) ​ $ (0.01) ​ $ (0.02) ​ $ (0.02) ​

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Stock Based Compensation
Schedule of share-based compensation stock options activity	Activity related to stock options and nonvested shares during the nine months ended September 30, 2021 and related balances outstanding as of that date are reflected below (in thousands): ​ ​ ​ ​ ​ ​ Stock Options Outstanding at January 1, 2021 25,000 Granted — Exercised and vested — Expired and forfeited — Outstanding at September 30, 2021 25,000 ​ ​ ​ Options vested at September 30, 2021 25,000 ​ ​ ​ Options exercisable at September 30, 2021 25,000

Description of Business (Detail

Description of Business (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Oct. 31, 2020
Description of Business [Line Items]
Amount of operating loss carry forward		$ 103,500,000		$ 103,500,000
Milestone Revenue	$ 409,430
Milestones receivable		$ 292,284
Royalty receivable			$ 31,000
Common Stock, Shares Authorized		170,000,000	170,000,000
Rights Offering
Description of Business [Line Items]
Rights Offering and realized in gross proceeds		$ 43,600,000

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Basis of Presentation
Provision for uncollectible accounts	$ 0
Liability for uncertain tax positions	$ 0

Financial Instruments and Fai_2

Financial Instruments and Fair Value (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Financial Instruments and Fair Value
Cash Equivalents, at Carrying Value	$ 43.6	$ 43.6
Minimum percent of assets in U.S.treasury bills, notes and other obligations	99.50%	99.50%

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Supplemental Cash Flow Information
Income Taxes Paid	$ 0	$ 0	$ 0	$ 0
Interest Paid, Net	$ 0		$ 0

Loss Per Common Share (Details)

Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Loss Per Common Share - Basic and Diluted:
Net loss	$ (226)	$ (19)	$ 11	$ (407)	$ (236)	$ (242)	$ (234)	$ (885)
Dividends on Series C preferred stock	(506)			0			(1,518)	0
Net loss available to common shareholders	$ (732)			$ (407)			$ (1,752)	$ (885)
Weighted-average number of common shares outstanding - Basic	74,215			44,215			74,215	44,215
Weighted-average number of common shares outstanding - Diluted	74,215			44,215			74,215	44,215
Basic loss per share	$ (0.01)			$ (0.01)			$ (0.02)	$ (0.02)
Diluted loss per share	$ (0.01)			$ (0.01)			$ (0.02)	$ (0.02)
Antidilutive securities	41,787			41,787			25,000	25,000

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stock Based Compensation
Nonvested shares outstanding	0	0
Nonvested shares granted	0	0
Stock-based compensation expense	$ 0
Outstanding at January 1, 2021	25,000
Granted	0	0
Exercised and vested	0
Expired and forfeited	0
Outstanding at September 30, 2021	25,000
Options vested at September 30, 2021	25,000
Options exercisable at September 30, 2021	25,000

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Oct. 31, 2020USD ($)
Income Taxes [Line Items]
Income Tax Expense (Benefit)	$ 0	$ 0	$ 2,000	$ 2,000
Operating Loss Carryforwards, Limitation on Annual Utilization			80
Operating Loss Carryforwards	103,500,000		$ 103,500,000		$ 103,500,000
Net Operating Loss Carry-Forwards Limitation On Annual Utilization			$ 103,500,000
Operating Loss Carryforwards, Year			20 years
Tax Credit Carryforward, Limitations on Use			net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income.
New jersey State [Member]
Income Taxes [Line Items]
Income Tax Expense (Benefit)	0	$ 0	$ 2,000	$ 2,000
NJ State [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	25,800,000		25,800,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 100,600,000		$ 100,600,000

Accounts Payable (Details)

Accounts Payable (Details) - Merck [Member] - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Accounts Payable [Line Items]
Net of royalty interest, percentage				25.00%
Accrued royalties				$ 302,000
Accrued royalties, current		$ 2,000	$ 27,000
Due to related parties, total	$ 331,000

Section 382 Rights Plan (Detail

Section 382 Rights Plan (Details)	Aug. 14, 2020Vote$ / sharesshares	Sep. 30, 2021$ / shares	Dec. 31, 2020$ / shares
Preferred stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Section 382 Rights Plan
Rights per share distributed as dividend | shares	1
Number of preferred stock purchase right for each common stockholder | shares	1
Section 382 Rights Plan | Series A-1 Junior Participating Preferred Stock
Number of preferred stock eligible for each warrant become exercisable | shares	1
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01
Purchase price per right | $ / shares	$ 1.20
Number of votes for fractional share | Vote	1

Rights Offering (Details)

Rights Offering (Details) - USD ($) $ / shares in Units, $ in Millions	Oct. 09, 2020	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share)			$ 0.01	$ 0.01
Number of preferred shares outstanding			0	0
Common stock, shares outstanding			74,214,603	74,214,603
Rights Offering
Class of Warrant or Right [Line Items]
Subscription price per unit of a right		$ 1,090
Number of preferred stock eligible for each warrant become exercisable		1
Number of subscription rights to be held for purchase of a unit		1,105
Number of units entitled for 1,105 subscription rights held		1
Rights Offering | Series C Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.01
Number of common shares for unit		750
Percentage of dividend on liquidation preference to be paid in cash				3.00%
Annual increase in percentage of the liquidation preference per share, if dividend not paid in cash				5.00%
Rights Offering | Icahn Capital LP
Class of Warrant or Right [Line Items]
Subscription price per unit of a right			$ 5,971
Rights Offering | Icahn Capital LP | Series C Preferred Stock
Class of Warrant or Right [Line Items]
Number of common shares for unit			33,306
Number of units sold that remains unsubscribed			24,979,500
Number of units sold			33,306
Number of preferred shares outstanding			4,478,250
Common stock, shares outstanding			5,971
Affiliates own			48.00%
Maximum percentage of common outstanding			98.00%
Rights Offering | Investment Agreement | Icahn Capital LP | Series C Preferred Stock
Class of Warrant or Right [Line Items]
Number of units sold	40,000
Number of preferred shares outstanding	40,000
Common stock, shares outstanding	74,214,603
Issued and gross proceeds	$ 43.6

Series C Preferred Stock - Addi

Series C Preferred Stock - Additional Information (Details) - Series C Preferred Stock - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	Dec. 31, 2020	Oct. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Jun. 30, 2021	Mar. 31, 2021
Stock Issued During Period, Shares, New Issues		40,000
Stock Issued During Period, Value, New Issues		$ 40,000,000
Preferred Stock, Liquidation Preference Percent	5.00%		5.00%
Preferred Stock, Liquidation Preference, Value			$ 506,000		$ 506,000	$ 506,000
Preferred Stock Cumulative Liquidation Value	$ 40,460,000		$ 41,978,000	$ 40,460,000
Preferred Stock, Liquidation Preference Per Share	$ 1,012		$ 13	$ 1,012	$ 13	$ 12
Rights Offering
Preferred Stock, Liquidation Preference, Value	$ 460,000			$ 460,000
Percentage of Dividend on Liquidation Preference				3.00%
Preferred Stock, Liquidation Preference Per Share	$ 1,000		1,050	$ 1,000
Annual Increase in Percentage of the Liquidation Preference Per Share, If Dividend Not Paid in Cash				5.00%
Preferred stock initial liquidation value			$ 1,000
Preferred stock dividends on liquidation value			$ 0